Abstract
Inflammatory flare-up reactions of some dermatomycoses, particularly those caused by zoophilic fungi, are typical and potentially severe adverse effects following the intake of some oral antifungals. However, this condition has not previously been reported with the most frequently used antifungals in dermatology, namely fluconazole, itraconazole, and terbinafine. In this report, we describe five patients, observed over a 10-year period, who presented with inflammatory exacerbations following oral antifungal therapy for dermatomycoses. We also review the literature on inflammatory reactions exacerbated by oral antifungal agents.
Details of the patients‘ age, sex, occupation, and atopic background; the site of the lesion, its clinical and histologic features, and any systemic signs; the identity of the fungal pathogen; the antifungal agent taken by the patient; the time between drug intake and occurrence of the flare-up; the approach to management; and the outcome were documented for each patient. A PubMed literature search was also conducted, focusing on inflammatory exacerbations induced by griseofulvin, ketoconazole, itraconazole, fluconazole, and terbinafine.
The patients were four farmers and one veterinarian (all male). All primary lesions were inflammatory dermatophytoses, including one kerion. Inflammatory exacerbation of the skin lesions started 12-24 hours after the intake of oral antifungals. Mild systemic changes, including slight fever and malaise, occurred in two cases. Itraconazole 400 mg/day was implicated as the causative agent in four cases and terbinafine 250 mg/day in one case. Mycologic cultures grew Trichophyton verrucosum in four cases. Antifungal treatment was discontinued in all patients. Oral and topical corticosteroids were administered to the two patients with systemic changes; the other three patients were treated with topical corticosteroids only. Two days after the onset of corticosteroids, lower doses of itraconazole (100 mg/day) and terbinafine (125 mg/day) were reintroduced. All lesions healed after 4–5 weeks. The PubMed search did not identify any articles that described inflammatory exacerbations of dermatomycoses induced by oral antifungals.
Inflammatory flare-up of dermatomycoses is a rare but potentially severe cutaneous complication of oral antifungal use. Occupational contact with animals, inflammatory dermatomycoses, and zoophilic fungi represent common features in these patients. Although evidence-based data are not available, clinical experience shows that, in addition to antifungal therapy, topical and/or systemic corticosteroids are helpful to reduce the inflammatory reactions. The cases described in this article represent the first published report of oral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis in patients taking itraconazole or terbinafine.
Similar content being viewed by others
References
Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52: 209–24
McClellan KJ, Wiseman LR, Markham A. Terbinafme: an update of its use in superficial mycoses. Drugs. 1999; 58: 179–202
Grant SM, Clissold SP. Ketoconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989; 37: 310–44
Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996; 51: 585–620
Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole. Exp Opin Pharmacother. 2000; 1: 287–304
Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs. 1995; 50: 658–90
Baran R, Gupta AK, Pierard GE. Pharmacotherapy of onychomycosis. Exp Opin Pharmacother. 2005; 6: 609–24
Bork K. Jarisch-Herxheimer reaction and ketoconazole. In: Bork K, editor. Cutaneous side effects of drugs. 1st ed. New York: WB Saunders Company, 1988: 24
Litt JZ. Drug eruption reference manual. 11th ed. New York: Taylor and Francis, 2005
Bryceson AD. Clinical pathology of the Jarisch-Herxheimer reaction. J Infect Dis. 1976; 133: 696–704
Melkert PW. Fatal-Jarisch Herxheimer reaction in a case of relapsing fever misdiagnosed as lobar pneumonia. Trop Geogr Med. 1987; 39: 92–3
Coxon RE, Fekade D, Knox K, et al. The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever. QJM. 1997; 90: 213–21
Kaplanski G, Granel B, Vaz T, et al. Jarisch-Herxheimer reaction complicating the treatment of chronic Q fever endocardifs: elevated TNFalpha and IL-6 serum levels. J Infect. 1998; 37: 83–4
Arnez M, Pleterski-Rigler D, Luznik-Bufon T, et al. Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien Klin Wochenschr. 2002; 114: 498–504
Gene M, Ledger WJ. Syphilis in pregnancy. Sex Transm Infect. 2000; 76: 73–9
Barriere H, Litoux P. Intérêt et justification de la corticothérapie générale dans la teigne suppurative. Ann Dermatol Venereol 1977; 104: 294–7
Nichter LS, Thomas DM, Atkinson J, et al. Scalp infections in black children: think kerion. Plast Reconstr Surg. 1987; 80: 717–9
Stephens CJ, Hay RJ, Black MM. Fungal kerion: total scalp involvement due to Microsporum canis infection. Clin Exp Dermatol. 1989; 14: 442–4
Munteanu M. Traitements pratiques des mycoses suppuratives de la peau et des mycoses allergiques cutanées dues au Candida. Rev Med Chir Soc Med Nat Iasi. 1990; 94: 631–4
Kick G, Korting HC. Debilitating folliculitis barbae candidomycetica in a trumpeter: successful treatment with fluconazole. Mycoses; 1998; 41: 339–42
Elewski BE, El Charif M, Copper KD, et al. Reactivity to trichophyton antigen in patients with onychomycosis: effect of terbinafine. J Am Acad Dermatol. 2002; 46: 371–5
Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther. 2005; 30: 291–5
Pomeranz AJ, Salmis SS. Tinea capitis: epidemiology, diagnosis and management strategies. Paediatr Drugs. 2002; 4: 779–83
Hassig A. Intravenous immunoglobulins: pharmacological aspects and therapeutic use. Vex Sang 1986; 51: 10–7
Remick DG, Negussie Y, Fekade D, et al. Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. J Infect Dis; 1996; 174: 627–30
Teklu B, Habte-Michael A, Warrell DA, et al. Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever. Lancet 1983; 1: 835–9
Cooper PJ, Fekade D, Remick DG, et al. Recombinant human interleukin-10 fails to alter proinflammatory cytokine production or physiologic changes associated with the Jarisch-Herxheimer reaction. J Infect Dis. 2000; 181: 203–9
Griffin GE. Cytokines involved in human septic shock: the model of the Jarisch-Herxheimer reaction. J Antimicrobial Chemotherapy. 1998; 41 Suppl. A: 25–9
Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med. 1996; 335: 311–5
Aste N, Pau M, Biggio P. Kerion celsi: a clinical epidemiological study. Mycoses 1998; 41: 169–73
Nolting S, Regatta K. Double-blind comparison of miconazole/corticosteroid combination versus miconazole in inflammatory dermatomycoses. Int J Dermalot. 1995; 34: 125–8
Acknowledgments
No sources of funding were used to assist in the preparation of this report. The authors have no conflicts of interest that are directly relevant to the content of this report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nikkels, A.F., Nikkels-Tassoudji, N. & Piérard, G.E. Oral Antifungal-Exacerbated Inflammatory Flare-Up Reactions of Dermatomycosis. Am J Clin Dermatol 7, 327–331 (2006). https://doi.org/10.2165/00128071-200607050-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200607050-00007